Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA Delegation Meets China Pharmaceutical Organizations

This article was originally published in PharmAsia News

Executive Summary

Representatives from the Pharmaceutical Research and Manufacturers of America recently attended an international summit in Beijing on new drug R&D policies and practices hosted by the Healthcare Policy Research Center of Chinese Pharmaceutical Association. The center expressed the wish of strengthening both countries' cooperation in drug production to the American delegation, which included top-level executives from key multinational companies such as Bristol-Myers Squibb, Lilly, Genzyme, GlaxoSmithKline, MSD Pharma (Merck's India arm), Novartis, Pfizer, Schering-Plough and Wyeth. The U.S. group held exchanges with officials from China's State FDA and the Ministry of Health on supervisory issues about developing new drugs globally and conducting multicenter clinical trials. Members from China Health & Medical Development Foundation, Chinese Pharmaceutical Association and China Pharmaceutical Industry Association also joined in discussions to boost collaboration. (Click here for more - Chinese Language)

You may also be interested in...

Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 

Pfizer Confirms EU Pegfilgrastim Launch Plans

Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts